NLS MedImmune

AstraZeneca plans to kick off a U.S. expansion anticipated to add 300 jobs so it can capitalize on a pipeline full of  strong candidates, which it is counting on to help return the company to growth by 2017. “Our global biologics research and development arm, MedImmune, has a robust pipeline of more than 120 biologics, […]

MedImmune, AstraZeneca’s global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has developed an imaging and data analysis technology known as Tissue Phenomics™. The new technology significantly improves the identification of biomarkers in tumor tissue. According to the agreement, MedImmune will acquire 100 percent of Definiens’ […]

AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue. Under the terms of the agreement, MedImmune will […]

AstraZeneca, together with its global biologics research and development arm, MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership. The new agreements build on the existing partnership between AstraZeneca, MedImmune and the University of Cambridge, which includes an oncology research programme and co-location of AstraZeneca scientists […]

AstraZeneca’s global biologics research and development arm MedImmune and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), has entered into a collaboration. The aim is to establish a joint laboratory in Cambridge, UK. The new laboratory will focus on the discovery and development of novel biologic cancer treatments over an initial five-year period. AstraZeneca announces that scientists […]

AstraZeneca has announced the start of the Phase III programme for tralokinumab, developed by MedImmune. Tralokinumab is a potential treatment for patients with severe, inadequately controlled asthma. The Phase III program will evaluate the safety and effectiveness of tralokinumab in reducing the rate of asthma exacerbations (AER) in adults and adolescents with severe, inadequately controlled asthma despite receiving […]